For GLP-1 analogues and DPP-4 inhibitors, a baseline assessment of pancreatic risk factors (e.g., triglyceride level, gallbladder status, alcohol use history) can be performed before initiating therapy, especially in patients with preexisting metabolic syndrome (Tenner et al., 2024). The gene discussed is DPP4; the disease is metabolic syndrome.